Vyndaqel (Tafamidis meglumine) for amyloidosis

Overview
Vyndaqel is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat adults with heart disease resulting from wild-type or hereditary (hATTR) amyloidosis. Vyndaqel is also referred to by its drug name, tafamidis meglumine.

Vyndaqel is a member of a class of drugs called selective transthyretin (TTR) stabilizers. Vyndaqel is believed to work by stabilizing TTR proteins, preventing them from separating and forming clumps that deposit in body tissues.

How do I take it?
Prescribing information states that Vyndaqel is given orally as a capsule once daily. It should be taken exactly as prescribed by the physician.

Side effects
The FDA-approved label for Vyndaqel lists no reported common side effects.

Fetal harm may be a serious side effect of Vyndaqel.

For more details about this treatment, visit:

Vyndaqel — Pfizer